UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
We evaluate long-term return potential across index funds to help you identify candidates with the strongest growth prospects.
28,522 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A loomingFed policy shift could push up borrowing costs for households. Analysts warn americans taxpayers could face ...
A growing number of retirees moved cash into Treasury bills to lock in near-4% yields. But the tax system on Social S...
As Pool Corp closes its Q4, investors weigh the implications for pool corp (pool) 2025. This guide breaks down the ea...
SanDisk shares jumped on fresh momentum as data-center demand and NAND constraints propel a potential multi-year rall...
Christie’s New York Spring Auction Week posted $1.45 billion in sales, led by a Pollock that fetched $181 million. Th...
A $1 million horror film defies expectations while a 30-year-old franchise returns with a bold new installment, deliv...
SoFi stock has dipped back toward the $18 area, prompting questions about a long-awaited recovery. This guide breaks ...
Rep. Ro Khanna told Suffolk graduates that AI wealth should benefit workers, not just the rich, amid rising job fears...
Institutional players are accelerating tokenization and on-chain strategies, even as many traditional investors lag b...
XRP trades near $1.45 as policy and liquidity headlines drive the 12-month outlook. Analysts map three potential path...
Figma stock shows signs of a potential rebound as profitability improves and AI-driven features gain traction, even a...